HBW Advisory Services LLC decreased its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 73.8% during the 1st quarter, Holdings Channel reports. The firm owned 1,594 shares of the financial services provider’s stock after selling 4,490 shares during the quarter. HBW Advisory Services LLC’s holdings in iShares Biotechnology ETF were worth $269,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the business. Darwin Wealth Management LLC bought a new stake in iShares Biotechnology ETF in the second quarter worth approximately $25,000. Basepoint Wealth LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter worth approximately $26,000. Cary Street Partners Financial LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter worth approximately $29,000. Copia Wealth Management acquired a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth approximately $34,000. Finally, Caitlin John LLC acquired a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Up 0.7%
NASDAQ:IBB opened at $189.90 on Thursday. The company has a fifty day moving average of $177.00 and a 200-day moving average of $173.16. iShares Biotechnology ETF has a twelve month low of $128.84 and a twelve month high of $199.05.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
